Commonwealth Equity Services
SABS icon

Commonwealth Equity Services’s SAB Biotherapeutics SABS Stock Holding History

Commonwealth Equity Services’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178K Buy
+46,455
New +$185K ﹤0.01% 4037
2024
Q1 		– Sell
-1,282
Closed -$9K – 4085
2023
Q4 		$9K Buy
+1,282
New +$10.7K ﹤0.01% 3869

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Commonwealth Equity Services's SABS Position: Q1 2026 in Review

Commonwealth Equity Services opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 46,455 shares worth $178K. The stake represents ﹤0.01% of the portfolio and ranks #4037 among its holdings. This is a return to the name: Commonwealth Equity Services previously reported a position in SABS as recently as Q4 2023.

Commonwealth Equity Services first reported a position in SABS in Q4 2023 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Commonwealth Equity Services held 46,455 shares of SAB Biotherapeutics worth $178K as of Q1 2026.
  • SAB Biotherapeutics was a new Commonwealth Equity Services position in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4037 holding.
  • Commonwealth Equity Services first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.